MarginsXMarginsX
Home › Markets › Health Care › LFCR

Lifecore Biomedical Inc. (LFCR)

LFCR trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$6.42
-0.08% on the day
Market cap
$243.2M
Micro cap
Revenue · 2024
$128.3M
+24.2% on 2023
Net income · 2024
$12.0M
9.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-KT (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2024-05-26, https://www.sec.gov/Archives/edgar/data/1005286/000100528626000009/0001005286-26-000009-index.htm. Net income: SEC 10-KT (us-gaap:NetIncomeLoss), fiscal year ended 2024-05-26.

Profile

FieldValue
TickerLFCR on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001005286
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2024

LineValue
Revenue$128.3M
Net income$12.0M
Operating income-$8.8M
Net margin9.4%
Operating margin-6.9%
Revenue growth+24.2%
Cash$8.5M
Total assets$254.0M
P/E (computed)20.2×
P/S (computed)1.9×

Warning signs

Cash runway
Cash-flow positive
$23.0M cash at September 30, 2026
Share count, 1 year
+1.2%
2025-10-30 to 2026-10-28
Going-concern doubt
No
10-Q filed November 4, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-04
Cash and burn$23.0M cash; operating cash flow $2.8M a quarter.Report 2026-09-30
Shares outstanding37,905,846 (2026-10-28); 37,466,352 a year earlier.Cover page 2026-10-28
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, Philadelphia, Pennsylvania, United States; changed auditors 1 time in 24 months8-K 4.01 2025-08-18
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q1 2027
2026-09-30
$25.3M-$40.1M$6.9M$23.0M$161.0MNeeds four quarters10-Q 2026-11-04
Q1 2027
2026-06-30
$34.2M-$6.2M-$2.2M$17.2M$155.1MNeeds four quarters10-Q 2026-08-05
Q3 2026
2026-03-31
$23.2M-$15.0M$4.7M$20.8M$148.7MNeeds four quarters10-Q 2026-05-06
Q1 2026
2025-09-30
$31.1M-$10.0M$1.8M$18.9M$136.0MNeeds four quarters10-Q 2026-11-04
Q4 2025
2025-05-25
$36.4M-$1.1M$5.3M$8.3M$130.4M$128.9M10-Q 2026-08-05
Q3 2025
2025-02-23
$35.2M-$14.8M$1.2M$5.4M$124.9M$130.3M10-Q 2026-05-06
Q2 2025
2024-11-24
$32.6M-$6.6M-$6.1M$9.5M$111.3M$130.9M10-Q 2025-01-02
Q1 2025
2024-08-25
$24.7M-$16.2M-$613K$5.5M$106.3M$128.4M10-Q 2025-11-06

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32025-09-30
Latest annual report10-KT2026-03-16
Latest quarterly / interim10-Q2026-11-04
Latest current report8-K2026-11-05
Latest proxyDEFM14A2026-11-13

Source: SEC EDGAR submissions feed, 1,005 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+0.9%
1 month0.0%
3 months+35.7%
Year to date-21.5%
1 year-18.6%
From 52-week high-27.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
CAMPCAMP4 Therapeutics Corporation$3.86+1.58%$242.2M
RCKTRocket Pharmaceuticals Inc.$2.16-6.09%$241.2M
BIOABioAge Labs Inc.$5.22-5.95%$239.9M
FTHFaeth Therapeutics Inc.$9.28-7.48%$239.8M
ARCTArcturus Therapeutics Holdings Inc.$8.31-0.60%$239.5M
QTTBQ32 Bio Inc.$8.29-4.82%$248.1M
AMRNAmarin Corporation plc$11.31-0.62%$233.4M
VNDAVanda Pharmaceuticals Inc.$3.81-4.51%$230.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier